https://www.sciencedaily.com/releases/2018/05/180517102236.htm “Intelligent brains possess lean, yet efficient neuronal connections,” concludes Erhan Genç. “Thus, they boast high mental performance at low neuronal activity.”
Brain abnormality indicates general risk for mental illness: A new study identifies functional connectivity impairments associated with transdiagnostic risk for common forms of mental illness — ScienceDaily
https://www.sciencedaily.com/releases/2018/05/180517102401.htm Authors conclude: “These patterns suggest that broad risk for mental illness may reflect subtle problems in how a person is able to integrate their thoughts, plans, and actions with their fundamental experience of the world, which in humans is principally represented by visual information,” said Mr. Elliott.
POEM: Nonopioids equivalent to opioids for severe chronic back, hip, or knee pain with fewer adverse outcomes
Begin forwarded message: From: “Joule – a CMA Company” <cma.ca> Subject: POEM: Nonopioids equivalent to opioids for severe chronic back, hip, or knee pain with fewer adverse outcomes Date: May 15, 2018 at 4:00:03 AM PDT To: “Joris Anton Josef Wiggers” <joriswiggers> Reply-To: cma.ca View the Web version POEMs Research Summaries Your daily update for […]
Read More »
Methamphetamine use and future risk for Parkinson’s disease: Evidence and clinical implications – Drug & Alcohol Dependence
https://www.drugandalcoholdependence.com/article/S0376-8716(18)30197-2/fulltext?dgcid=raven_jbs_etoc_email basically, its a real problem: Watch for PD emergence in former meth addiction.
https://www.medscape.com/viewarticle/896510?nlid=122292_329&src=WNL_mdplsnews_180511_mscpedit_psyc&uac=27343DV&spon=12&impID=1630260&faf=1#vp_3 Timeline for S-ketamine intranasal spray, (Janssen), could file for product release by end of the year. Great hype. Low side effects. Good Phase 3 trial data released this month. We are hopeful to use it within 1 year? Game changer? Biggest psychopharma intro in 50 years? Lots of hype…
https://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2017.pp11a3 This is a landmark study for treatment of depression: They are now moving the benchmark to third line treatment for ECT; that is, after two failed trials of two antidepressants or one antidepressant and one psychotherapy, patient would go on to ECT. This is very aggressive, but the projected models show distinct improvement in […]
Read More »
Targeting Safety Behaviors in the Treatment of Anxiety Disorders: A Case Study of False Safety Behavior Elimination Treatment: American Journal of Psychotherapy: Vol 0, No 0
https://psychotherapy.psychiatryonline.org/doi/10.1176/appi.psychotherapy.20180001?utm_campaign=email&utm_source=etoc&utm_medium=textlink&utm_content=ajp This five-session protocol seems perfect for a busy practice like mine, in which a precise and direct approach to anxiety might forestall any unnecessary use of pills. I am intrigued and contacted the author for more info.
May 8, 2018 A link to the following Medscape article was sent to you by: joris wiggers May need replcation Genetic Test Identifies Best Antidepressant Medscape Medical News, 2018-05-05 WebMD, LLC 825 Eighth Avenue New York, NY 10019 http://www.medscape.com